KLRC1 and cancer: Whether SINEs also specifically activates NKG2A+ T cells against cancer cells has not been addressed although they can enhance the anti-tumour activity of CD19 directed CAR T cells against multiple lymphoma cell lines [109] and TRAIL-R2xCD3 bispecific antibodies against breast cancer cells [110].